Dalpiciclib in HR+/HER2- ABC

Summary

To evaluate the efficacy and safety of dalpiciclib in patients with HR-positive/HER2-positive advanced breast cancer.

Eligibility

Inclusion Criteria:

* Histologically confirmed advanced breast cancer
* Hormone receptor-positive and human epidermal growth factor receptor 2-negative
* ECOG 0-1

Exclusion Criteria:

* Pregnant or breastfeeding
* History of immunodeficiency

Conditions3

Interventions1

Related trials

• A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer. — Risen (Suzhou) Pharma Tech Co., Ltd.
• Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer — Tongji Hospital
• Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer — Fudan University
• Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC） — Hebei Medical University Fourth Hospital
• Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer — Hebei Medical University Fourth Hospital
• Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer — Sun Yat-sen University
• Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer — The First Affiliated Hospital with Nanjing Medical University
• Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer — Hebei Medical University Fourth Hospital

Browse More Trials